A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo)
Publication
, Journal Article
Morse, MA; Babich, JW; LaFrance, N; Kacena, KA; Gockerman, J; Moore, J; Coleman, RE
Published in: Journal of Clinical Oncology
May 20, 2008
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
4605 / 4605
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Babich, J. W., LaFrance, N., Kacena, K. A., Gockerman, J., Moore, J., & Coleman, R. E. (2008). A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo). Journal of Clinical Oncology, 26(15_suppl), 4605–4605. https://doi.org/10.1200/jco.2008.26.15_suppl.4605
Morse, M. A., J. W. Babich, N. LaFrance, K. A. Kacena, J. Gockerman, J. Moore, and R. E. Coleman. “A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4605–4605. https://doi.org/10.1200/jco.2008.26.15_suppl.4605.
Morse MA, Babich JW, LaFrance N, Kacena KA, Gockerman J, Moore J, et al. A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):4605–4605.
Morse, M. A., et al. “A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 4605–4605. Crossref, doi:10.1200/jco.2008.26.15_suppl.4605.
Morse MA, Babich JW, LaFrance N, Kacena KA, Gockerman J, Moore J, Coleman RE. A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):4605–4605.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
4605 / 4605
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences